8-KLeadership ChangesExhibits & Filings

BOSTON SCIENTIFIC CORP 8-K Report, Executive Changes (Feb 26, 2007)

Filed February 26, 2007For Securities:BSX

Summary

Boston Scientific Corporation (BSX) filed an 8-K on February 26, 2007, detailing significant changes to executive compensation and retention agreements. The Compensation Committee approved an amendment to the definition of 'Change in Control' within executive retention agreements, shifting the trigger from shareholder approval to the actual consummation of a reorganization, merger, consolidation, or similar transaction. This provides greater clarity and certainty regarding the conditions under which these agreements become active for executive officers. Additionally, the company approved an amendment to its 2007 Performance Incentive Plan, introducing an incentive compensation recoupment policy. This policy ensures that if the company's financial statements are restated and would result in a reduction of a previously awarded incentive payment, the company can seek reimbursement from executive officers for any excess amounts paid based on the original, un-restated financials. These changes reflect a proactive approach to corporate governance and executive accountability.

Key Highlights

  • 1Amendment to 'Change in Control' definition in executive retention agreements, now triggered by consummation of transaction rather than shareholder approval.
  • 2Introduction of an incentive compensation recoupment policy within the 2007 Performance Incentive Plan.
  • 3The recoupment policy allows the company to seek reimbursement if financial restatements reduce previously paid incentive awards.
  • 4These changes apply to executive officers of Boston Scientific Corporation.
  • 5The Compensation Committee of the Board of Directors approved these amendments.
  • 6The filing includes the amended form of Retention Agreement and the amended 2007 Performance Incentive Plan as exhibits.

Frequently Asked Questions

The definition of 'Change in Control' in executive retention agreements has been amended. Previously, shareholder approval of a transaction would trigger the agreement. Now, it is the actual consummation (completion) of a reorganization, merger, consolidation, or similar arrangement involving the company that will trigger the agreement.

The 2007 Performance Incentive Plan has been amended to include a recoupment policy. This means that if Boston Scientific's financial statements are later restated and the restatement would have resulted in lower incentive payments to executives, the company can reclaim the excess amounts that were originally paid.

These changes are important as they enhance corporate governance and executive accountability. The clearer definition of 'Change in Control' reduces ambiguity, and the recoupment policy provides a mechanism to recover compensation paid based on potentially inaccurate financial information, aligning executive incentives more closely with actual company performance.

The amendments were approved by the Compensation Committee of the Board of Directors on February 20, 2007. The company intends to ask each executive officer to sign an amended Retention Agreement, and the 2007 Performance Incentive Plan as amended is applicable to executive officers.